Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab combined with XELOX as neoadjuvant therapy for locally advanced gastric cancer
ChiCTR2200057850Phase 2Not yet recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, oxaliplatin and capecitabine in gastric cancer (GC) and gastric adenocarcinoma, sponsored by Henan Provincial People's Hospital. Primary endpoints: Overall response rate, Disease-free survival and 1 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
sintilimaboxaliplatincapecitabine
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200057850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057850.